Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 3Glioblastoma 3Gliosarcoma 2Brain Neoplasms 2Prostatic Neoplasms 1Pain 1Oligodendroglioma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Glioma 1Carcinoma, Renal Cell 1Astrocytoma 1

Interventions

Fentanyl 27Analgesia 23Morphine 20Acupuncture Therapy 18Surveys and Questionnaires 16Oxycodone 16Zoledronic Acid 15Acetaminophen 14Therapeutics 13Radiotherapy 13Psychiatric Rehabilitation 13Ketamine 13Methadone 11Lidocaine 11Hydromorphone 11Bupivacaine 11nabiximols 10Ibandronic Acid 10Ropivacaine 9Early Intervention, Educational 7Analgesics, Opioid 7Saline Solution 6Music Therapy 6Cryotherapy 6Cryosurgery 6Yoga 5Water 5Tapentadol 5Pregabalin 5Methods 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pain × tandutinib × Clear all
NCT00390468 2014-05-28

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

National Cancer Institute (NCI)

Phase 2 Completed
18 enrolled 5 charts
Genitourinary

Neoplasm Metastasis, Pain, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡